Skip to content

REGENEREX PHARMA, INC.: 10-Q filed 2024-11-04

What REGENEREX PHARMA, INC. reported in its quarterly report filed 2024-11-04 (fiscal Q2 2024): 31 published measures, 85 facts as tagged in accession 0001472375-24-000090.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-04
Fiscal period
fiscal Q2 2024
Accession
0001472375-24-000090 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGENEREX PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-30632,954USD
At 2024-03-31766,680USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-305,390,117USD
At 2024-03-314,828,506USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-4,757,163USD
At 2024-06-30-4,313,389USD
At 2024-03-31-4,061,826USD
At 2023-09-30-3,633,333USD
At 2023-06-30-1,083,968USD
At 2023-03-31-1,122,947USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-30294USD
At 2024-03-31372USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-529,572USD92
2024-04-01 to 2024-09-30-802,132USD183
2024-04-01 to 2024-06-30-272,560USD91
2023-07-01 to 2023-09-30-2,801,449USD92
2023-04-01 to 2023-09-30-2,987,024USD183
2023-04-01 to 2023-06-30-185,575USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-04-01 to 2024-09-30-181,938USD183
2023-04-01 to 2023-09-30-293,286USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-04-01 to 2024-09-30181,860USD183
2023-04-01 to 2023-09-30304,530USD183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-04-01 to 2023-09-30-6,299USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-6,417,982USD
At 2024-03-31-5,615,850USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-30278,281,562shares92
2024-04-01 to 2024-09-30278,254,052shares183
2023-07-01 to 2023-09-30277,516,358shares92
2023-04-01 to 2023-09-30277,337,306shares183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-09-305,232USD
At 2024-03-316,097USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-04-01 to 2024-09-3056,795USD183
2023-04-01 to 2023-09-30133,388USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-258,384USD92
2024-04-01 to 2024-09-30-512,664USD183
2023-07-01 to 2023-09-30-2,785,923USD92
2023-04-01 to 2023-09-30-2,946,097USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-301,835USD
At 2024-03-312,912USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-07-01 to 2024-09-30266,157USD92
2024-04-01 to 2024-09-30288,490USD183
2023-07-01 to 2023-09-3019,801USD92
2023-04-01 to 2023-09-3038,307USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-304,850,523USD
At 2024-03-313,843,362USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-30154,616USD
At 2024-03-31116,760USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-09-30208USD
At 2024-03-311,328USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-30258,384USD92
2024-04-01 to 2024-09-30512,664USD183
2023-07-01 to 2023-09-302,785,923USD92
2023-04-01 to 2023-09-302,946,097USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2023-09-302,400,000USD92
2023-04-01 to 2023-09-302,400,000USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-30278,435,910shares
At 2024-03-31278,225,910shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-30294USD
At 2024-03-31372USD
At 2023-09-306,080USD
At 2023-03-311,135USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-301,382,383USD
At 2024-03-311,275,798USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-09-30625,679USD
At 2024-03-31756,343USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-09-302,465USD
At 2024-03-311,600USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-09-30126,328USD
At 2024-03-3197,251USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30258,384USD92
2024-04-01 to 2024-09-30512,664USD183
2023-07-01 to 2023-09-30385,923USD92
2023-04-01 to 2023-09-30546,097USD183

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-04-01 to 2024-09-301,985USD183
2023-04-01 to 2023-09-301,975USD183

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-07-01 to 2024-09-30405USD92
2024-04-01 to 2024-09-301,120USD183
2023-07-01 to 2023-09-30723USD92
2023-04-01 to 2023-09-301,437USD183

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-271,188USD92
2024-04-01 to 2024-09-30-289,468USD183
2023-07-01 to 2023-09-30-15,526USD92
2023-04-01 to 2023-09-30-40,927USD183

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-09-3070,086USD183
2023-04-01 to 2023-09-3092,993USD183

Inspect the source

Entity
REGENEREX PHARMA, INC. / CIK 0001357878
Captured
2026-09-21T17:18:44.819Z
SEC response SHA-256
213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))